Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of recombinant botulinum toxin type A injection (JHM03) for adult upper limb spasticity
CTR20243194Phase 2Completed
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Sep 2024
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in upper extremity spasticity, sponsored by Junhemeng Biopharmaceutical. Started Sep 2024; status: completed.
02
Drugs
JHM03
03
Conditions
upper extremity spasticity
Beyond the preview
Go deeper on CTR20243194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243194.